Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
IF
NASDAQ · IFRX
InflaRx N.V.
Healthcare · Biotechnology
$2.02
Up+$0.02 (+0.99%)
Updated Sep 17, 2026, 12:27 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 69.1M
- P/E ratio
- -1.3
- Dividend yield
- 0.00%
- 52-week range
- $0.80 – $2.95
- Volume
- 579.6K
- Avg. volume
- 2.87M
Price performance
IFRX price history
1M range · 19 trading sessions · Daily adjusted prices
IFRX closed at $2.02 after 19 trading sessions, down 4.72% for the selected period.
- Last close
- $2.02
- Period change
- -4.72%
- Period low
- $2.02
- Period high
- $2.46
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.12 | $2.165 | $1.99 | $2.02 | 579.6K |
| Sep 14, 2026 | $2.15 | $2.20 | $2.10 | $2.12 | 545.79K |
| Sep 11, 2026 | $2.07 | $2.11 | $2.04 | $2.09 | 334.15K |
| Sep 10, 2026 | $2.05 | $2.07 | $1.98 | $2.05 | 613.48K |
| Sep 9, 2026 | $2.15 | $2.15 | $2.05 | $2.09 | 759.75K |
| Sep 8, 2026 | $2.19 | $2.26 | $2.11 | $2.17 | 408.9K |
| Sep 4, 2026 | $2.21 | $2.3767 | $2.16 | $2.22 | 393.94K |
| Sep 3, 2026 | $2.30 | $2.3705 | $2.18 | $2.23 | 666.37K |
| Sep 2, 2026 | $2.16 | $2.34 | $2.1326 | $2.29 | 572.04K |
| Sep 1, 2026 | $2.12 | $2.27 | $2.09 | $2.16 | 475.08K |
| Aug 31, 2026 | $2.21 | $2.23 | $2.09 | $2.13 | 447.81K |
| Aug 28, 2026 | $2.28 | $2.37 | $2.21 | $2.23 | 610.42K |
| Aug 27, 2026 | $2.40 | $2.4349 | $2.245 | $2.27 | 1.41M |
| Aug 26, 2026 | $2.45 | $2.50 | $2.33 | $2.42 | 1.71M |
| Aug 25, 2026 | $2.06 | $2.46 | $2.01 | $2.46 | 3.89M |
| Aug 24, 2026 | $2.10 | $2.11 | $2.03 | $2.05 | 337.02K |
| Aug 21, 2026 | $2.03 | $2.12 | $2.025 | $2.10 | 419.9K |
| Aug 20, 2026 | $2.12 | $2.15 | $2.005 | $2.02 | 587.74K |
| Aug 19, 2026 | $2.18 | $2.22 | $2.09 | $2.12 | 958.32K |
Latest IFRX news
The latest Smart Investors Daily articles mentioning IFRX.
Stock researchCompany · Overview
IFRX research
Overview
Company profile and research snapshot.
Company profile
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | Needham | Buy | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| May 13, 2026 | Raymond James | Strong Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 11, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 6, 2026
InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates
InflaRx Q2 2026 misses estimates; EPS -$0.095 vs -$0.060, revenue nil. Stock falls pre-market but pipeline advances with izicopan.
Benzinga · Aug 6, 2026
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same
Benzinga · Jun 30, 2026
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
